Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8442993 | European Journal of Cancer | 2014 | 11 Pages |
Abstract
The incremental cost per QALY gained indicates that panitumumab plus mFOLFOX6 represents good value for money in comparison to bevacizumab plus mFOLFOX6 and, with a willingness-to-pay ranging from â¬40,000 to â¬60,000, can be considered cost-effective in first-line treatment of patients with wild-type RAS mCRC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christopher N. Graham, Guy Hechmati, Jonas Hjelmgren, Frédérique de Liège, Julie Lanier, Hediyyih Knox, Beth Barber,